Business Wire

MN-ENTRUST-DATACARD

11.2.2020 15:02:10 CET | Business Wire | Press release

Share
Entrust Datacard Simplifies High-Assurance Authentication With Next Generation Passwordless Workforce Login and Fully Digital Customer Identity Proofing

Entrust Datacard , a leading provider of trusted identity and secure issuance technology solutions, today announced two new high-assurance offerings for the company’s unified authentication management platform: Passwordless Single Sign On (SSO) Authentication to improve workforce security and productivity, and Identity Proofing with fully digital identity verification for accelerated customer acquisition and onboarding.

As digital transformation, cloud deployments and mobile initiatives make communication, data storage and remote workstyles dramatically simpler, employees and customers around the world expect security features to follow suit, without compromising user experiences. The latest Entrust Datacard authentication solutions both increase high-assurance security and simplify user experiences.

Entrust Datacard’s Passwordless SSO Authentication solution turns employee smartphones into biometrics-protected virtual smart cards that allow instant proximity-based login to both workstations and applications. The solution creates a frictionless authentication experience, eliminating passwords and putting an end to the risk of bad actors stealing user credentials and compromising critical information.

Taking passwordless login to an SSO experience removes the friction of individual registrations and logins for each device, allowing employees to work across devices and applications – cloud-based and on-premises. The solution improves workforce productivity by enabling employees to securely conduct their work activities – email signing, file encryption, document signing, and more – from their office or remote location without the need to upgrade their hardware or operating system.

Entrust Datacard’s new Identity Proofing solution lets banks, hospitals, government agencies and other customer and citizen-facing organizations offer customers a simple, seamless onboarding experience, either inside or outside physical locations. With Identity Proofing, customers use their smartphones or a kiosk to capture their images and scan government-issued identity documents – such as a driver’s license, passport or national ID card – for fast, AI-based authentication and verification.

Once authenticated and verified, the user can complete their account application securely. This minimizes abandoned account applications, cuts onboarding time from multiple days to minutes and has the potential to reduce an organization’s onboarding costs from hundreds of dollars per account to single digits. The fully digital Identity Proofing solution supports compliance with regional regulations, such as Know Your Customer (KYC) and Anti-Money Laundering (AML) in the United States, and PSD2 in Europe.

“Digital transformation is driving the demand for authentication that is both incredibly easy and highly secure – features once thought incompatible,” said James LaPalme, VP and GM of Authentication at Entrust Datacard. “By delivering passwordless SSO authentication, enterprises can eliminate passwords and transform the employee experience, while increasing privacy and data security. Similarly, our Identity Proofing solution creates a truly digital customer onboarding experience, streamlining and automating what has until now been a costly, manual and less-secure process behind the scenes.”

To learn more about the Entrust Datacard Passwordless SSO Authentication and Identity Proofing solutions visit RSA Conference booth #S-2139 from February 24-28 at the Moscone Center in San Francisco or head to https://www.entrustdatacard.com/products/categories/authentication .

About Entrust Datacard Corporation

Consumers, citizens and employees increasingly expect anywhere-anytime experiences — whether they are making purchases, crossing borders, accessing e-gov services or logging onto corporate networks. Entrust Datacard offers the trusted identity and secure issuance technologies that make those experiences reliable and secure. Solutions range from the physical world of financial cards, passports and ID cards to the digital realm of authentication, certificates, hardware security modules and secure communications. With more than 2,800 Entrust Datacard colleagues around the world, and a network of strong global partners, the company serves customers in 150 countries worldwide. For more information, visit www.entrustdatacard.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye